Valvular Aortic Valve articles

Trombólisis local en tromboembolismo pulmonar

Device Evolution Also Impacts on Valve in Valve

Device Evolution Also Impacts on Valve in Valve

TAVR to treat dysfunctional biological prosthetics (ViV) with the last generation self-expandable supra-annular prosthetic offers excellent results both clinical and hemodynamic. In addition, there were additional reductions of paravalvular regurgitation compared against the original models.  The present registry published in JAHA is the most extensive to treat this issue and replicate outcomes from the clinical

valve_in_valve

Failed Aortic Bioprosthesis: Valve in Vale or Repeat Surgery?

The Valve in Valve (ViV) technique seems to be a better option than repeat surgery for failed aortic bioprosthesis. While this strategy lacks long-term evidence to address issues such as durability, it is considered as an option especially for young patients. ViV to treat failed surgical bioprosthesis has shown lower in-hospital mortality compared with repeat

Retos en TAVI- Enfermedad coronaria severa y oclusión coronaria

Watch Again Challenges in TAVR – Severe Coronary Disease and Coronary Occlusion

Watch Again Challenges in TAVR – Severe Coronary Disease and Coronary Occlusion on our youtube account. Challenges in TAVR – Severe Coronary Disease and Coronary Occlusion

Webinar SOLACI-CACI-MicroPort

SOLACI-CACI 2021 Webinar | Challenges in TAVI – Severe CAD & Coronary Occlusion

Next Thursday, October 14, we will hold a joint event between SOLACI, CACI and the Microport company on “Challenges in TAVI: Severe Coronary Disease and Coronary Occlusion”. The activity is part of the satellite events of the SOLACI-CACI 2021 Congress and, as such, will have the participation of important international and Latin American speakers. Date:

More Keys to Define Moderate Aortic Stenosis

Amidst the current efforts to prove early intervention might have benefits in moderate aortic stenosis (AS), this trial comes along directing us back to basics.  In patients with symptomatic aortic stenosis, peaking mortality will clearly justify intervention. But what is the case when there are no symptoms? According to this recent analysis published in JAMA,

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

The FDA Approves a Third Device in the TAVR Race

The Portico self-expanding graft has obtained FDA approval and can now compete as one of the three options available in clinical practice for transcatheter aortic valve replacement (TAVR) in the United States. For the time being, its indication will have some restrictions: for example, it can only be used in high-risk patients (unlike CoreValve and

Last articles on TAVR

The latest scientific articles on TAVI published on our website

01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Read also HERE 02-

Bivalirudina Heparina Anticoagulantes

TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?

In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Cardiologists, hematologists, clinicians, and

La revascularización incompleta se asocia a mortalidad en el TAVI

Thrombotic and Bleeding Risk after TAVR: Quick Tips to Stay Up to Date

Transcatheter aortic valve replacement (TAVR) is an increasingly frequent option for patients with severe aortic stenosis across the entire risk spectrum.  However, TAVR involves bleeding and thrombosis risk and therefore calls for an optimal adjuvant treatment.  Any scheme is complex if we take into account most patients undergoing TAVR are generally elderly and have multiple

autoexpandible

SAPIEN 3 Ultra: Lower Incidence of Paravalvular Regurgitation?

Paravalvular regurgitation after transcatheter aortic valve replacement (TAVR) have historically been associated with worse clinical outcomes. Even mild leaks have been shown to be harmful.  This study looked at a real-world experience with the transcatheter heart valve SAPIEN 3 Ultra in the US.  The SAPIEN 3 Ultra is a new generation balloon-expandable heart valve with

ESC 2021 | ENVISAGE-TAVI AF: sorpresas con el endoxaban en TAVI y fibrilación auricular

ESC 2021 | ENVISAGE-TAVI AF: Surprise with Endoxaban in TAVR and Atrial Fibrillation

The enthusiasm for direct oral anticoagulants after transcatheter aortic valve replacements (TAVR) is waning. At least, when it combines with atrial fibrillation. The ENVISAGE-TAVI AF has shown excessive bleeding with endoxaban vs. the classical vitamin K antagonists. Endoxaban resulted non-inferior to vitamin K antagonists in terms of net clinical adverse events, but major bleeding events

Top